Aprea Therapeutics Inc. has announced updates on its ongoing clinical trials for two investigational cancer therapies, APR-1051 and ATRN-119. In the Phase 1 ACESOT-1051 dose-escalation trial of APR-1051, a WEE1 kinase inhibitor, 3 out of 4 patients at the 100 mg once daily dose level achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies. Dose escalation has continued to the 150 mg once daily cohort. For ATRN-119, an ATR kinase inhibitor, the recommended Phase 2 dose (RP2D) has been identified as 1,100 mg once daily in the ABOYA-119 dose-escalation study. Results from these studies were presented in posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025. Future studies may evaluate APR-1051 in combination with checkpoint inhibitors.